In last trading session, Avadel Pharmaceuticals plc (NASDAQ:AVDL) saw 0.83 million shares changing hands with its beta currently measuring 1.39. Company’s recent per share price level of $8.77 trading at $0.17 or 1.98% at ring of the bell on the day assigns it a market valuation of $847.45M. That closing price of AVDL’s stock is at a discount of -117.67% from its 52-week high price of $19.09 and is indicating a premium of 27.25% from its 52-week low price of $6.38. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.92 million shares which gives us an average trading volume of 1.18 million if we extend that period to 3-months.

For Avadel Pharmaceuticals plc (AVDL), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.00. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 8 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.07 in the current quarter.

Avadel Pharmaceuticals plc (NASDAQ:AVDL) trade information

Upright in the green during last session for gaining 1.98%, in the last five days AVDL remained trading in the green while hitting it’s week-highest on Friday, 04/25/25 when the stock touched $8.77 price level, adding 0.34% to its value on the day. Avadel Pharmaceuticals plc’s shares saw a change of -16.56% in year-to-date performance and have moved 9.22% in past 5-day. Avadel Pharmaceuticals plc (NASDAQ:AVDL) showed a performance of 7.34% in past 30-days. Number of shares sold short was 9.68 million shares which calculate 9.98 days to cover the short interests.

Wall Street analysts have assigned a consensus price target of 21 to the stock, which implies a rise of 58.24% to its current value. Analysts have been projecting 19 as a low price target for the stock while placing it at a high target of 30. It follows that stock’s current price would drop -116.65% in reaching the projected high whereas dropping to the targeted low would mean a loss of -116.65% for stock’s current value.

Avadel Pharmaceuticals plc (AVDL) estimates and forecasts

This year revenue growth is estimated to rise 47.33% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 50.57M for the same. And 9 analysts are in estimates of company making revenue of 58.21M in the next quarter. Company posted 27.18M and 41.5M of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.39% during past 5 years.

Avadel Pharmaceuticals plc (NASDAQ:AVDL)’s Major holders

Insiders are in possession of 4.92% of company’s total shares while institution are holding 84.98 percent of that, with stock having share float percentage of 89.38%. Investors also watch the number of corporate investors in a company very closely, which is 84.98% institutions for Avadel Pharmaceuticals plc that are currently holding shares of the company. JANUS HENDERSON GROUP PLC is the top institutional holder at AVDL for having 13.3 million shares of worth $187.06 million. And as of 2024-06-30, it was holding 13.8296 of the company’s outstanding shares.

The second largest institutional holder is POLAR CAPITAL HOLDINGS PLC, which was holding about 6.56 million shares on 2024-06-30. The number of shares represents firm’s hold over 6.823 of outstanding shares, having a total worth of $92.24 million.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and JANUS INVESTMENT FUND-Janus Henderson Global Life Sciences Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.81 shares of worth $24.68 million or 2.91% of the total outstanding shares. The later fund manager was in possession of 2.54 shares on Dec 31, 2024 , making its stake of worth around $22.29 million in the company or a holder of 2.63% of company’s stock.